There’s nothing like ending a week on a high note but with today’s news of giant Boeing making plans to restart production in Washington state and with Gilead Sciences issuing a good report on their new drug to treat COVID-19, the Dow surged over 700 points.  The news sent waves of hope through the market at the prospect that it might not have to wait for a vaccine for this crisis to end; there might actually be a treatment on the horizon.  The S&P has now recovered 2/3 of the losses since the March low as reopening guidelines provide some hope and optimism.  Volume came in at just over 12.7 billion, a modest but first uptick in a while, but it’s on optimism instead of panic. 

Fri  APRIL 17, 2020 / 5:16  pm 

Wall Street gains on Boeing surge and coronavirus drug hopes

Caroline Valetkevitch

DJ:  23,537.68  +33.33        NAS:  8,532.36  +139.18        S&P:  2,799.55  +16.19     4/16

DJ:  24,242.49  +704.81      NAS:  8,650.14  +117.78        S&P:  2,874.56  +75.01     4/17

(Reuters) - U.S. stocks rose on Friday and also posted gains for the week, boosted by a surge in Boeing shares, President Donald Trump’s plan to reopen the coronavirus-battered economy and hopes of a potential drug by Gilead to treat COVID-19.  The Nasdaq added 6.1% for the week and registered its biggest two-week percentage gain since 2001.

Boeing (BA.N) shares soared nearly 15% on plans to restart commercial jet production in Washington state after halting operations last month due to the COVID-19 pandemic.

Gilead Sciences Inc (GILD.O) surged almost 10% following a report that patients with severe symptoms of COVID-19, the respiratory disease caused by the coronavirus, had responded positively to its experimental drug remdesivir. The report cited partial data from a University of Chicago hospital, one 152 locations participating in the trial. 

With no treatments or vaccines currently approved for the coronavirus, the news helped lift global equity markets. But Gilead said the totality of the data from the trial needed to be analyzed, and it expected to report results from a study testing the drug in severe COVID-19 patients at the end of April.  “If you can ultimately get a powerful treatment in lieu of a vaccine in the next couple of months, that would be good for cyclical stocks, anything economically sensitive,” said R.J. Grant, head of trading at Keefe, Bruyette & Woods in New York. “If we can get some sort of back-to-normal in some way that the economy could start to function, the banks are going to rip,” he added. 

The S&P 500 is up nearly 30% from its March trough following a raft of global stimulus and hopes that the spread of the virus was nearing a peak in the United States.  However, the S&P remains about 15% off its all-time high, and strategists have warned of a deep economic slump from the halt in business activity and layoffs.

Some U.S. states are expected to begin announcing timetables for lifting restrictions. On Thursday, Trump unveiled guidelines for a staggered, three-stage process by states to lift restrictions on business and social life to curb the pandemic.

The Dow Jones Industrial Average .DJI rose 704.81 points, or 2.99%, to 24,242.49, the S&P 500 .SPX gained 75.01 points, or 2.68%, to 2,874.56 and the Nasdaq Composite .IXIC added 117.78 points, or 1.38%, to 8,650.14.  For the week, the Dow added 2.2% and the S&P 500 rose 3%. 

The reopening guidelines “provide some hope and optimism for folks and the market and the whole economy. It’s a start,” said Gary Bradshaw, portfolio manager at Hodges Capital Management in Dallas.  Bradshaw, who owns Boeing shares, said the planemaker’s news was positive as well. “I certainly haven’t given up on it,” he said.

Bank stocks recovered after four straight days of losses triggered by lenders’ reporting several billion dollars in reserves to cover potential loan defaults. The S&P 500 financial index .SPSY ended up 5.6%, while the S&P energy index .SPNY jumped 10.4%.  Apple Inc (AAPL.O) fell 1.4% as Goldman Sachs downgraded the stock on expectations of a 36% drop in iPhone shipments during the company’s fiscal third quarter due to coronavirus-related lockdowns.

Volume on U.S. exchanges was 12.75 billion shares, compared to the 13.72 billion average for the full session over the last 20 trading days.

Advancing issues outnumbered declining ones on the NYSE by a 5.18-to-1 ratio; on Nasdaq, a 3.88-to-1 ratio favored advancers.  The S&P 500 posted 10 new 52-week highs and no new lows; the Nasdaq Composite recorded 31 new highs and 13 new lows.